School of Medicine
Tel: 353 1 803 4447
Assistant Professor Harvard Medical School, Boston, USA 2010-2014
Attending Physician Massachusetts General Hospital, Boston, USA 2010-2014
Prof. Michaela Higgins has been a Consultant
Medical Oncologist at the Mater Misericordiae University Hospital since 2015,
with specialty interest in breast and lung cancers. Previous to this she was an
Assistant Professor of Medicine at Harvard Medical School and an Attending
(Consultant) Physician at Massachusetts General Hospital, Boston. Her cancer
research has been awarded competitive funding by the U.S. Department of
Defense, The Conquer Cancer Foundation and the Avon Foundation. Prof. Higgins
has led numerous national and international clinical trials for patients with
cancer. Her research has been awarded multiple competitive grants and she has
over 40 manuscripts in peer-reviewed journals. Prof. Higgins is a member of
Cancer Research UK¿s Clinical Trials Awards and Advisory Committee and the
Mater Hospital Lung Cancer Working Group. She serves on the UCD Clinical
Research Centre Executive Committee.
UCD Medicine Research Individual Investigator
Honours and Awards
| Year: 2012.
Title: Career Development Award
| Year: 2010.
Title: Merit Award
| Year: 2009.
Title: Young Investigator Award
| Year: 2002.
Title: First Class Honours in Medicine at Final MB Examination
| Year: 2002.
Title: Sean Malone Medal in Psychiatry
| Year: 2002.
Title: McCarthy Medal in Surgery
| Year: 2002.
Title: Magennis Gold Medal in Clinical Medicine
| Year: 2001.
Title: Tobin Prize in Surgery
| Year: 2001.
Title: Dargan Prize in Medicine
|Association: American Society of Clinical Oncology, Function/Role: Member|
|Association: Royal College of Physicians in Ireland, Function/Role: Member|
|Committee : UCD Clinical Research Centre Executive Committee|
|Committee : Mater Hospital Lung Cancer Working Group|
Peer Reviewed Journals
|Agarwal N, Machiels JP;Su¿¿rez C;Lewis N;Higgins M;Wisinski K;Awada A;Maur M;Stein M;Hwang A;Mosher R;Wasserman E;Wu G;Zhang H;Zieba R;Elmeliegy M (2016) 'Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer'. Oncologist, 21 (5):535-536. [DOI] [Details]|
|Chavarri-Guerra Y, Higgins MJ;Szymonifka J;Cigler T;Liedke P;Partridge A;Ligibel J;Come SE;Finkelstein D;Ryan PD;Goss PE (2014) 'Drug withdrawal in women with progressive metastatic breast cancer while on aromatase inhibitor therapy'. British Journal of Cancer, 111 (11):2046-2050. [DOI] [Details]|
|Sarangi S, Mosulpuria K;Higgins MJ;Bardia A (2014) 'The Evolving Role of Circulating Tumor Cells in the Personalized Management of Breast Cancer: from Enumeration to Molecular Characterization'. Current Breast Cancer Reports, 6 (3):146-153. [DOI] [Details]|
|Fathi AT, Sadrzadeh H;Comander AH;Higgins MJ;Bardia A;Perry A;Burke M;Silver R;Matulis CR;Straley KS;Yen KE;Agresta S;Kim H;Schenkein DP;Borger DR (2014) 'Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate'. Oncologist, 19 (6):602-607. [DOI] [Details]|
|Beaver JA, Jelovac D;Balukrishna S;Cochran RL;Croessmann S;Zabransky DJ;Wong HY;Valda Toro P;Cidado J;Blair BG;Chu D;Burns T;Higgins MJ;Stearns V;Jacobs L;Habibi M;Lange J;Hurley PJ;Lauring J;VanDenBerg DA;Kessler J;Jeter S;Samuels ML;Maar D;Cope L;Cimino-Mathews A;Argani P;Wolff AC;Park BH (2014) 'Detection of cancer DNA in plasma of patients with early-stage breast cancer'. Clinical Cancer Research, 20 (10):2643-2650. [DOI] [Details]|
|Higgins MJ, Liedke PE;Goss PE (2013) 'Extended adjuvant endocrine therapy in hormone dependent breast cancer: the paradigm of the NCIC-CTG MA.17/BIG 1-97 trial'. Critical Reviews in Oncology/Hematology, 86 (1):23-32. [DOI] [Details]|
|Higgins MJ, Jelovac D;Barnathan E;Blair B;Slater S;Powers P;Zorzi J;Jeter SC;Oliver GR;Fetting J;Emens L;Riley C;Stearns V;Diehl F;Angenendt P;Huang P;Cope L;Argani P;Murphy KM;Bachman KE;Greshock J;Wolff AC;Park BH (2012) 'Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood'. Clinical Cancer Research, 18 (12):3462-3469. [DOI] [Details]|
|Lee BL, Higgins MJ;Goss PE (2012) 'Denosumab and the current status of bone-modifying drugs in breast cancer'. Acta Oncologica, 51 (2):157-167. [DOI] [Details]|
|Higgins MJ, Baselga J (2011) 'Targeted therapies for breast cancer'. Journal of Clinical Investigation, 121 (10):3797-3803. [DOI] [Details]|
|Higgins MJ, Baselga J (2011) 'Breast cancer in 2010: Novel targets and therapies for a personalized approach'. Nature Reviews Clinical Oncology, 8 (2):65-66. [DOI] [Details]|
|Higgins MJ, Stearns V (2011) 'Pharmacogenetics of endocrine therapy for breast cancer'. Annual Review of Medicine, 62 :281-293. [DOI] [Details]|
|Schapira L, Higgins MJ (2011) 'All nodes lead to chemo'. Oncologist, 16 (5):722-725. [DOI] [Details]|
Dr Higgins acts as local PI for several Cancer Trials Ireland clinical studies available for lung and breast cancer patients at the Mater hospital, Dublin. She also is leading a pilot exosome biomarker study in women with triple negative breast cancer which is being co-led with Dr. Amanda McCann in the Conway Institute
| Dr. Amanda McCann (Conway Institute, UCD)
|Cancer Trials Ireland|